Research programme: inflammation therapy - Chiesi USA

Drug Profile

Research programme: inflammation therapy - Chiesi USA

Alternative Names: Anti-HMBG1 Mab; Anti-HMGB-1 MAb

Latest Information Update: 06 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Critical Therapeutics
  • Developer Chiesi USA
  • Class Monoclonal antibodies
  • Mechanism of Action High mobility group protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammation; Rheumatoid arthritis; Septic shock

Most Recent Events

  • 28 Apr 2014 Cornerstone Therapeutics is now called Chiesi USA
  • 04 Feb 2014 Cornerstone Therapeutics has been acquired by Chiesi Farmaceutici
  • 11 Apr 2011 Research programme: inflammation therapy - Cornerstone Therapeutics is available for licensing as of 06 Jul 2010. http://www.crtx.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top